DebioPharm's Salvacyl launched in EU for sexual deviancy
This article was originally published in Scrip
Executive Summary
DebioPharm has launched its gonadotropin releasing hormone (GnRH) agonist analogue Salvacyl (extended-release triptorelin), for the treatment of sexual deviancy by the reversible reduction of serum testosterone to castrate levels, in Germany and Belgium.